Meeting
2015 ASCO Annual Meeting
Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.
Authors
Chan-Young Ock
Seoul National University Hospital, Seoul, South Korea
Chan-Young Ock , Eunkyung An , Do-Youn Oh , Tae-Yong Kim , Kyung-Hun Lee , Sae-Won Han , Seock-Ah Im , Tae-You Kim , Wei-Li Liao , Fabiola Cecchi , Adele Blackler , Sheeno P Thyparambil , William Arthur Hoos , Woo Ho Kim , Jon Burrows , Todd A. Hembrough , Yung-Jue Bang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4050)
DOI
10.1200/jco.2015.33.15_suppl.4050
Abstract #
4050
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
First Author: Seyoung Seo
Poster
2017 Gastrointestinal Cancers Symposium
Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy.
First Author: Shusuke Yagi
Poster
2015 ASCO Annual Meeting
HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).
First Author: Paolo Nuciforo
Poster
2014 ASCO Annual Meeting
Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.
First Author: Paolo Nuciforo